Rates of failure among patients with a MCyR and a concomitant CHR versus patients without a CHR (neither concomitant nor ever-achieved)
| Phase (no. McyR) . | No. (%) . | P . | |
|---|---|---|---|
| McyR + CHRc . | Failure . | ||
| AP (31) | .27 | ||
| Yes | 19 (61) | 10 (53) | |
| No | 12 (39) | 9 (75) | |
| BP (21) | .05 | ||
| Yes | 6 (29) | 3 (50) | |
| No | 15 (71) | 14 (93) | |
| ALL (3) | NA | ||
| Yes | 1 (33) | 1 (100) | |
| No | 2 (67) | 2 (100) | |
| Overall (55) | .02 | ||
| Yes | 26 (47) | 14 (54) | |
| No | 29 (53) | 25 (86) | |
| Phase (no. McyR) . | No. (%) . | P . | |
|---|---|---|---|
| McyR + CHRc . | Failure . | ||
| AP (31) | .27 | ||
| Yes | 19 (61) | 10 (53) | |
| No | 12 (39) | 9 (75) | |
| BP (21) | .05 | ||
| Yes | 6 (29) | 3 (50) | |
| No | 15 (71) | 14 (93) | |
| ALL (3) | NA | ||
| Yes | 1 (33) | 1 (100) | |
| No | 2 (67) | 2 (100) | |
| Overall (55) | .02 | ||
| Yes | 26 (47) | 14 (54) | |
| No | 29 (53) | 25 (86) | |
McyR + CHRc indicates MCyR with a concomitant CHR; and NA, not applicable.